Capricor Therapeutics (CAPR) Misses Q4 EPS by 11c

Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.62), $0.11 worse than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• UBS Reiterates Buy Rating on Levi Strauss & Co. (LEVI) Ahead of Q3 Results
• KB Home (KBH) PT Lowered to $50 at RBC Capital